These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30147005)

  • 1. Buprenorphine MAT as an Imperfect Fix.
    Mund B; Stith K
    J Law Med Ethics; 2018 Jun; 46(2):279-291. PubMed ID: 30147005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal buprenorphine patch: Potential for role in management of opioid dependence.
    Dhawan A; Modak T; Sarkar S
    Asian J Psychiatr; 2019 Feb; 40():88-91. PubMed ID: 30772733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
    Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
    J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable Buprenorphine (Probuphine) for Maintenance Treatment of Opioid Use Disorder.
    Goodbar NH; Hanlon KE
    Am Fam Physician; 2018 May; 97(10):668-670. PubMed ID: 29763278
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
    Bridge TP; Fudala PJ; Herbert S; Leiderman DB
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S79-85. PubMed ID: 12738352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine implants (Probuphine) for opioid dependence.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):94-5. PubMed ID: 27403784
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the treatment of opioid dependence: continued progress and ongoing challenges.
    O'Connor PG
    JAMA; 2010 Oct; 304(14):1612-4. PubMed ID: 20940391
    [No Abstract]   [Full Text] [Related]  

  • 12. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 13. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 18. Treating prescription opioid dependence.
    Ruetsch C
    JAMA; 2014 Sep; 312(11):1145-6. PubMed ID: 25226480
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescription opioid dependence: the clinical challenge.
    Newman RG
    JAMA Psychiatry; 2014 Mar; 71(3):338. PubMed ID: 24599244
    [No Abstract]   [Full Text] [Related]  

  • 20. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic.
    Straub A; Pastor A; Lloyd-Jones M; O'Neill H; Bonomo Y
    Drug Alcohol Rev; 2021 May; 40(4):681-682. PubMed ID: 32898928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.